These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 7620222)
1. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Patterson LH; Craven MR; Fisher GR; Teesdale-Spittle P Oncol Res; 1994; 6(10-11):533-8. PubMed ID: 7620222 [TBL] [Abstract][Full Text] [Related]
2. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity. Lee HH; Wilson WR; Denny WA Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270 [TBL] [Abstract][Full Text] [Related]
3. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844 [TBL] [Abstract][Full Text] [Related]
4. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. Siim BG; Hicks KO; Pullen SM; van Zijl PL; Denny WA; Wilson WR Biochem Pharmacol; 2000 Oct; 60(7):969-78. PubMed ID: 10974206 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides. Henderson ND; Plumb JA; Robins DJ; Workman P Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108 [TBL] [Abstract][Full Text] [Related]
6. 1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation. Antonini I; Polucci P; Jenkins TC; Kelland LR; Menta E; Pescalli N; Stefanska B; Mazerski J; Martelli S J Med Chem; 1997 Nov; 40(23):3749-55. PubMed ID: 9371240 [TBL] [Abstract][Full Text] [Related]
7. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs. Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490 [TBL] [Abstract][Full Text] [Related]
8. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102 [TBL] [Abstract][Full Text] [Related]
9. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I. Papadopoulou MV; Ji M; Rao MK; Bloomer WD Oncol Res; 1997; 9(5):249-57. PubMed ID: 9306432 [TBL] [Abstract][Full Text] [Related]
10. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423 [TBL] [Abstract][Full Text] [Related]
11. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448 [TBL] [Abstract][Full Text] [Related]
12. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632 [TBL] [Abstract][Full Text] [Related]
13. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Patterson LH Cancer Metastasis Rev; 1993 Jun; 12(2):119-34. PubMed ID: 8375016 [TBL] [Abstract][Full Text] [Related]
14. Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: synthesis and biological evaluation. Yin H; Xu Y; Qian X; Li Y; Liu J Bioorg Med Chem Lett; 2007 Apr; 17(8):2166-70. PubMed ID: 17331719 [TBL] [Abstract][Full Text] [Related]
15. Novel N-oxides as bioreductive drugs. Naylor MA Oncol Res; 1994; 6(10-11):483-91. PubMed ID: 7620216 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449 [TBL] [Abstract][Full Text] [Related]
17. Novel antitumor agent family of 1H-benzo[c,d]indol-2-one with flexible basic side chains: synthesis and biological evaluation. Yin H; Xu Y; Qian X Bioorg Med Chem; 2007 Feb; 15(3):1356-62. PubMed ID: 17129733 [TBL] [Abstract][Full Text] [Related]
18. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides. Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668 [TBL] [Abstract][Full Text] [Related]
19. Antitumor agents 4. Characterization of free radicals produced during reduction of the antitumor drug 5H-pyridophenoxazin-5-one: an EPR study. Alberti A; Bolognese A; Guerra M; Lavecchia A; Macciantelli D; Marcaccio M; Novellino E; Paolucci F Biochemistry; 2003 Oct; 42(41):11924-31. PubMed ID: 14556623 [TBL] [Abstract][Full Text] [Related]
20. 1, 2, 4-Triazine N-oxide derivatives: studies as potential hypoxic cytotoxins. Part III. Cerecetto H; González M; Risso M; Saenz P; Olea-Azar C; Bruno AM; Azqueta A; De Ceráin AL; Monge A Arch Pharm (Weinheim); 2004 May; 337(5):271-80. PubMed ID: 15095420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]